Skip to content
Operation Infinite Justice – Lifestyle
Author:
Nurix Therapeutics, Inc.
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
July 21, 2026
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 9, 2026
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
June 11, 2026
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
June 8, 2026
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
May 14, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conferences
May 13, 2026
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
May 12, 2026
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
April 22, 2026
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
April 8, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conference
April 7, 2026
1
2
Next Page
→